Quote:

---

“We are delighted to have been selected by Innovation Pharmaceuticals to scale up and industrialize the production of Brilacidin, a phase 3 drug compound advancing in multiple development programs under Fast Track designations and look forward to contribute to the success of this franchise,” said Dr. Andreas Meudt, Vice President, Product Line Exclusive Synthesis at Evonik’s Health Care Business Line.

---

If this was stated in a PR made by Evonik I would have chalked it up to them just talking about another partner and not knowing the exact details of the pipeline. This was in the IPIX PR though.

Is this a slip of some important information? Intended? Unintended? My understanding is Brilacidin is technically not yet a phase 3 drug in any indication. Does this portend great things or am I reading too much into an imprecise casual comment by an exec at another company? I feel like IPIX has been dotting I's and crossing T's with all their public information as of late. They wouldn't let that slip by in a PR issued by themselves.

This, of course, has even bigger implications when you consider we likely won't be starting a phase 3 without a partner.